NEW YORK, NY (March 8, 2019)—TB Alliance’s new drug application (NDA) for the novel tuberculosis (TB) drug candidate pretomanid has been accepted for review by the United States Food and Drug Administration (FDA). The application is for…Original Article
You may also like
Scientists Race to Test Treatments as Ebola Outbreak...
The New Race to Find Treatments for Measles
Medical Advances Are Keeping a Health Reporter Busy
As Ebola Spreads, Scientists Race to Find Vaccines and...
A Loophole Brings Cystic Fibrosis Patients a...
Could Lowering Inflammation Treat Depression?
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.
